Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer
Genomic classifiers such as the Genomic Prostate Score (GPS) could help to personalize treatment for men with intermediate-risk prostate cancer (I-PCa). In this study, we aimed to evaluate the ability of the GPS to change therapeutic decision making in I-PCa. Only patients in the intermediate NCCN r...
Main Authors: | Yazid Belkacemi, Kamel Debbi, Gabriele Coraggio, Jérome Bendavid, Maya Nourieh, Nhu Hanh To, Mohamed Aziz Cherif, Carolina Saldana, Alexandre Ingels, Alexandre De La Taille, Gokoulakrichenane Loganadane |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/3/945 |
Similar Items
-
Misanian Men, are or aren't a Prostatic Adenocarcinoma?
by: Haider Qasim Alhelfi
Published: (2021-04-01) -
Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice
by: Bannakij Lojanapiwat
Published: (2014-09-01) -
Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer
by: Ahmad Chaddad, et al.
Published: (2018-07-01) -
Extraprostatic extension of gleason 6 prostate cancer: single center experience
by: Onur Ceylan, et al.
Published: (2021-06-01) -
Evaluation Expression COX-2 in Prostatic Carcinoma by PCR and Immunohistochemistry and Its Relationship with Gleason Score
by: Maryam Ghiasi, et al.
Published: (2021-05-01)